Please login to the form below

Not currently logged in

miRagen Therapeutics bolsters senior leadership team

Adam Levy and Christopher Mori take on new roles

miRagen Therapeutics Adam LevyColorado-based miRagen Therapeutics has expanded its senior leadership team with the appointments of Adam Levy as chief business officer, succeeding Christopher Mori who now becomes chief operating officer.

Levy (pictured right) joins the clinical-stage biopharmaceutical company from Wedbush Securities, a healthcare banking group, where he served as senior vice president from 2013.

Prior to this, Levy held positions of increasing responsibility in investment banking at Merrill Lynch and Jeffries, working primarily in the life sciences sector.

Meanwhile, Mori (pictured below) brings over 25 years of strategic and operational experience to his new role at miRagen Therapeutics.

Prior to joining as chief business officer, Mori served as interim chief financial officer at Alethia Biotherapeutics, where he currently serves as an independent director.

miRagen Christopher MoriHe has held a number of executive leadership positions, including chief operating officer at Ambit Biosciences Corporation and vice president of business development at Agensys, and spent 20 years at GlaxoSmithKline in a variety of roles.

Levy said: “With two novel programmes in the clinic and a focus on diseases with high unmet medical need, I believe miRagen is poised to make a difference in the lives of patients.

“I am excited to join this talented team and contribute to the success of miRagen Therapeutics as we develop our pipeline of product candidate across multiple disease areas.”

14th June 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge